Mefloquine revisited

Hardly any other antimalarial drug's safety that is currently used for chemoprophylaxis in travelers has been so passionately debated as mefloquine's over the past two decades [1]. Formulated at the Walter Reed Army Institute of Research in the 1970s, and becoming commercially available for prophylactic use in Europe in 1985 and the US in 1990, mefloquine has since been widely used as one of the main antimalarials recommended in travelers for this purpose [2]. Mefloquine's safety profile yet in particular its subsequent association with neurologic or psychiatric adverse events including psychosis and suicide have since raised great concerns among many prescribers and patients alike, and have received significant media attention [3].
Source: Travel Medicine and Infectious Disease - Category: Infectious Diseases Authors: Source Type: research